A Comparison of Additional Benefit Scores in Germany (Gba) and France (HAS)

A Comparison of Additional Benefit Scores in Germany (Gba) and France (HAS)

2014 Value in health

Soussi, I. | Thivolet, M. | Kornfeld, A. | Brunet, J. | Toumi, M. | Volume: 17, Issue: 7, Pages: A430, France, Germany, Value,

The Pharmaceutical Market Restructuring Act (AMNOG) has brought a sustainable change to the reimbursement of new drugs in Germany. The G-BA assesses the additional benefit of the drug, compared to an appropriate therapy. AMNOG law is perceived to be one of the toughest drug evaluation process in Europe. In France the high authority for health (HAS) assesses the level of improvement of actual benefit (IAB). The objective of this study was to compare the additional benefit score issued under AMNOG law to IAB scores granted by the HAS.

https://www.doi.org/10.1016/j.jval.2014.08.1092; 10.1016/j.jval.2014.08.1092